Kobi M. Sethna, President and Chief Executive Officer, Member of the Board of Directors
Mr. Sethna is a globally experienced, pharmaceutical industry general manager with more than 30 years of successful research-driven product development and product marketing experience. During his career, Mr. Sethna has held executive level responsibility for various business segments and geographic regions. He has also served at the corporate level in senior executive marketing positions and has had responsibility for clinical research, regulatory affairs, manufacturing and business development.

For most of his career, Mr. Sethna was a vice president of the Lederle Pharmaceutical Division of American Cyanamid International. In this capacity he directed multidisciplinary, global, therapeutic-specific business teams with particular emphasis in the areas of oncology, anti-infectives, anti-inflammatory and cardiovascular medicine for both hospital and office practice use. Mr. Sethna also completed an assignment with ICN Pharmaceuticals, as group vice president and general manager, to assist the company in the establishment of certain western hemisphere operations and business development.

Before joining Lederle, Mr. Sethna held progressively senior management positions in the US and overseas with Pfizer and Parke-Davis (Warner Lambert).

Mr. Sethna holds a bachelor's degree in pharmacy and an master's degree in pharmaceutical marketing from The Ohio State University. He serves as Vice chairman of the Board of Trustees of the Sidney Kimmel Cancer Center in San Diego, California, is a member of the Advisory Board of the College of Biological Sciences UCSD, and a Trustee of the Center of Integrative Medicine of Scripps Hospital.

G. Kenneth Lloyd, Ph.D., Senior Vice President, R & D, and Chief Scientific Officer

Dr. Lloyd has more than 30 years of experience in the pharmaceutical industry with a successful track record of team building, drug discovery and drug development in both major pharmaceutical and biotechnology companies. Prior to joining Nereus, Dr. Lloyd served as vice president of biology and drug discovery at SIBIA Neurosciences, Inc., as assistant vice president at Wyeth-Ayerst Research and as associate director at Synthelabo Recherche. Dr. Lloyd has over 200 scientific publications and serves on several scientific advisory boards and scientific review panels.

Dr. Lloyd received his bachelor's and master's degrees from McGill University and his Ph.D. in pharmacology from the University of Toronto.

Michael A. Palladino, Jr., Ph.D., Senior Vice President, Chief Technology Officer and Scientific Co-founder

Dr. Palladino is a cell biologist with more than 25 years of biotechnology industry experience who has made significant contributions to the understanding of the roles of cytokines/growth factors in the development of inflammatory diseases and cancer. Prior to founding Nereus, he served as Director of Cell Biology and Research Strategies at Genentech and Vice President of Preclinical Development at Applied Molecular Evolution and was responsible for directing the development of multiple products that progressed into clinical testing. Dr. Palladino has over 250 scientific publications and numerous patents. He has served on multiple scientific journal editorial boards and ACS and NIH/NCI study sections.

Dr. Palladino received his bachelor’s degree from Saint Peter’s College, a masters degree from Fairleigh Dickenson University and his doctorate from New York University. He held post-doctoral fellowships at NYU and Memorial Sloan Kettering Cancer Center. Prior to joining Genentech, he was a Research Associate at Memorial and the recipient of an American Cancer Society Junior Faculty Research Award.
 

Howard T. Holden, Ph.D., Senior Vice President, Regulatory Affairs and Compliance

Dr. Holden has more than 23 years of experience in regulatory affairs and compliance in pharmaceutical and biotechnology companies. During his time in the industry, he has built and led regulatory and compliance functions for programs from IND to NDA, BLA, and MAA; developed and implemented regulatory drug development and compliance strategies; and obtained approval for several products in the U.S., Europe and Canada. Prior to joining Nereus, Dr. Holden was Vice President of Regulatory Affairs and Compliance at Stressgen Biotechnologies and Ligand Pharmaceuticals, Senior Director at Parke-Davis/Warner-Lambert, Director at Centocor and Senior Investigator at the National Cancer Institute. Dr. Holden has over 120 publications on tumor immunology and natural host resistance.

Dr. Holden received his bachelor's degree from Drew University and his Ph.D. in microbiology from the University of Miami, School of Medicine.

Donald J. Salz, Vice President, Finance and Administration

Mr. Salz has more than 18 years of senior level financial management experience in the health care services industry and management consulting. This includes eight years of experience with health care-related companies ranging from early stage start-up ventures to multi-billion dollar companies. Previously, he was with Arthur Andersen as an audit manager in its health care group.

Mr. Salz earned his bachelor's degree in accounting from the University of Northern Iowa and earned his certified public account certificate.

Gary McDaniel, Chief Information Officer

Mr. McDaniel has over 20 years of biopharmaceutical experience in both drug discovery research and scientific informatics. Prior to joining Nereus, Mr. McDaniel held positions at SIBIA Neurosciences and Merck Research Laboratories where he was responsible for the computer hardware and software systems in high throughput screening and in the research computing department at the La Jolla site. Previously, Mr. McDaniel developed tumor-associated antigen hybridomas and then moved into developing laboratory information systems at Hybritech, which was acquired by Eli Lilly.

At Nereus, Mr. McDaniel has developed enterprise-level data systems to manage and provide access to the large volume of data generated in the drug discovery process.

Mr. McDaniel holds a bachelor’s degree in computer science from National University.